Characterization of cognitive impairment in adult polyglucosan body disease.

Adult polyglucosan body disease Cognitive impairment Dementia GBE1 Glycogen-branching enzyme

Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 15 12 2021
accepted: 03 01 2022
revised: 02 01 2022
pubmed: 10 1 2022
medline: 24 5 2022
entrez: 9 1 2022
Statut: ppublish

Résumé

Adult polyglucosan body disease (APBD) is a rare but probably underdiagnosed autosomal recessive neurodegenerative disorder due to pathogenic variants in GBE1. The phenotype is characterized by neurogenic bladder dysfunction, spastic paraplegia, and axonal neuropathy. Additionally, cognitive symptoms and dementia have been reported in APBD but have not been studied systematically. Using exome sequencing, we identified two previously unreported bi-allelic missense GBE1 variants in a patient with severe memory impairment along with the typical non-cognitive symptoms. We were able to confirm a reduction of GBE1 activity in blood lymphocytes. To characterize the neuropsychological profile of patients suffering from APBD, we conducted a systematic review of cognitive impairment in this rare disease. Analysis of 24 cases and case series (in total 58 patients) showed that executive deficits and memory impairment are the most common cognitive symptoms in APBD.

Identifiants

pubmed: 34999962
doi: 10.1007/s00415-022-10960-z
pii: 10.1007/s00415-022-10960-z
pmc: PMC9119871
doi:

Types de publication

Journal Article Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2854-2861

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : HE 8803/1-1
Organisme : Deutsche Forschungsgemeinschaft
ID : 418081722
Organisme : Deutsche Forschungsgemeinschaft
ID : 433158657

Informations de copyright

© 2022. The Author(s).

Références

Souza PVS et al (2021) GBE1-related disorders: Adult polyglucosan body disease and its neuromuscular phenotypes. J Inherit Metab Dis 44(3):534–543. https://doi.org/10.1002/jimd.12325
doi: 10.1002/jimd.12325 pubmed: 33141444
Mochel F et al (2012) Adult polyglucosan body disease: natural history and key magnetic resonance imaging findings. Ann Neurol 72(3):433–441. https://doi.org/10.1002/ana.23598
doi: 10.1002/ana.23598 pubmed: 23034915 pmcid: 4329926
Hellmann MA et al (2015) Frequent misdiagnosis of adult polyglucosan body disease. J Neurol 262(10):2346–2351. https://doi.org/10.1007/s00415-015-7859-4
doi: 10.1007/s00415-015-7859-4 pubmed: 26194201
Boulan-Predseil P, Vital A, Brochet B, Darriet D, Henry P, Vital C (1995) Dementia of frontal lobe type due to adult polyglucosan body disease. J Neurol. https://doi.org/10.1007/BF00867422
doi: 10.1007/BF00867422 pubmed: 8530979
Farmer JG, Crain BJ, Harris BT, Turner RS (2013) Coexisting adult polyglucosan body disease with frontotemporal lobar degeneration with transactivation response DNA-binding protein-43 (TDP-43)-positive neuronal inclusions. Neurocase 19(1):67–75
doi: 10.1080/13554794.2011.654217 pubmed: 22506890
Klein CJ et al (2004) Adult polyglucosan body disease: case description of an expanding genetic and clinical syndrome. Muscle Nerve 29(2):323–328. https://doi.org/10.1002/mus.10520
doi: 10.1002/mus.10520 pubmed: 14755501
Lee K, Ernst T, Løhaugen G, Zhang X, Chang L (2017) Neural correlates of adaptive working memory training in a glycogen storage disease type-IV patient. Ann Clin Transl Neurol 4(3):217–222. https://doi.org/10.1002/acn3.394
doi: 10.1002/acn3.394 pubmed: 28275655 pmcid: 5338158
Lossos A et al (1991) Hereditary branching enzyme dysfunction in adult polyglucosan body disease: a possible metabolic cause in two patients. Ann Neurol 30(5):655–662. https://doi.org/10.1002/ana.410300505
doi: 10.1002/ana.410300505 pubmed: 1763891
Robertson NP, Wharton S, Anderson J, Scolding NJ (1998) Adult polyglucosan body disease associated with an extrapyramidal syndrome. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp.65.5.788
doi: 10.1136/jnnp.65.5.788 pubmed: 9810960 pmcid: 2170425
Savage G, Ray F, Halmagyi M, Blazely A, Harper C (2007) Stable neuropsychological deficits in adult polyglucosan body disease. J Clin Neurosci. https://doi.org/10.1016/j.jocn.2006.03.001
doi: 10.1016/j.jocn.2006.03.001 pubmed: 16730990
Ubogu EE et al (2005) Adult polyglucosan body disease: a case report of a manifesting heterozygote. Muscle Nerve. https://doi.org/10.1002/mus.20384
doi: 10.1002/mus.20384 pubmed: 16007674
Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71
doi: 10.1136/bmj.n71 pubmed: 33782057 pmcid: 8005924
Zimmermann P, Fimm B (1993) Testbatterie zur Aufmerksamkeitsprüfung (TAP). Psytest, Freiburg
Thalmann B et al. (1997) CERAD - Consortium to Establish a Registry for Alzheimer’s Disease Assessment Battery - deutsche Fassung (CERAD-NP-Testbatterie; Consortium to Establish a Registry for Alzheimer’s Disease-Neuropsychological Assessment Battery (CERAD-NAB)). (PSYNDEX Tests Review)
Härting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J (2000) WMS-R - Wechsler Gedächtnistest - revidierte Fassung
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198
doi: 10.1016/0022-3956(75)90026-6 pubmed: 1202204
Falb RJ et al (2021) Bi-allelic loss-of-function variants in KIF21A cause severe fetal akinesia with arthrogryposis multiplex. J Med Genet. https://doi.org/10.1136/jmedgenet-2021-108064
doi: 10.1136/jmedgenet-2021-108064 pubmed: 34740919
Richards S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. https://doi.org/10.1038/gim.2015.30
doi: 10.1038/gim.2015.30 pubmed: 25741868 pmcid: 4544753
Berkhoff M, Weis J, Schroth G, Sturzenegger M (2001) Extensive white-matter changes in case of adult polyglucosan body disease. Neuroradiology. https://doi.org/10.1007/s002340000425
doi: 10.1007/s002340000425 pubmed: 11305757
Bit-Ivan EN et al (2014) Adult polyglucosan body disease with GBE1 haploinsufficiency and concomitant frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. https://doi.org/10.1111/nan.12144
doi: 10.1111/nan.12144 pubmed: 24750115 pmcid: 4177303
Bruno C et al (1993) Glycogen branching enzyme deficiency in adult polyglucosan body disease. Ann Neurol. https://doi.org/10.1002/ana.410330114
doi: 10.1002/ana.410330114 pubmed: 8494336
Franco-Palacios M et al (2016) Adult polyglucosan body disease with reduced glycogen branching enzyme activity and heterozygous GBE1 mutation mimicking a low-grade glioma. Int J Clin Exp Pathol 9(3):4092–4100
Gray F, Gherardi R, Marshall A, Janota I, Poirier J (1988) Adult polyglucosan body disease (APBD). J Neuropathol Exp Neurol. https://doi.org/10.1097/00005072-198807000-00007
doi: 10.1097/00005072-198807000-00007 pubmed: 2838589
Harigaya Y et al (2017) Novel GBE1 mutation in a Japanese family with adult polyglucosan body disease. Neurol Genet 3(2):138. https://doi.org/10.1212/NXG.0000000000000138
doi: 10.1212/NXG.0000000000000138
Lee S-Y, Park J-H, Kim SH, Kim T-S, Kim W-J, Choi Y-C (2007) A case of adult polyglucosan body disease. Yonsei Med J. https://doi.org/10.3349/ymj.2007.48.4.701
doi: 10.3349/ymj.2007.48.4.701 pubmed: 18159607 pmcid: 2628199
López Chiriboga AS (2017) Teaching neuroimages: prominent spinal cord atrophy and white matter changes in adult polyglucosan body disease. Neurology. https://doi.org/10.1212/WNL.0000000000003945
doi: 10.1212/WNL.0000000000003945 pubmed: 29038139
Lossos A et al (1998) Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol. https://doi.org/10.1002/ana.410440604
doi: 10.1002/ana.410440604 pubmed: 9851430
Massa R, Bruno C, Martorana A, de Stefano N, van Diggelen OP, Federico A (2008) Adult polyglucosan body disease: proton magnetic resonance spectroscopy of the brain and novel mutation in the GBE1 gene. Muscle Nerve. https://doi.org/10.1002/mus.20916
doi: 10.1002/mus.20916 pubmed: 18816606
Rifai Z et al (1994) Dementia of adult polyglucosan body disease. Evidence of cortical and subcortical dysfunction. Arch Neurol. https://doi.org/10.1001/archneur.1994.00540130124021
doi: 10.1001/archneur.1994.00540130124021 pubmed: 8274116
Robitaille Y, Carpenter S, Karpati G, DiMauro SD (1980) A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora’s disease and normal ageing. Brain. https://doi.org/10.1093/brain/103.2.315
doi: 10.1093/brain/103.2.315 pubmed: 6249438
Sagnelli A et al (2014) Adult polyglucosan body disease in a patient originally diagnosed with Fabry’s disease. Neuromuscul Disord. https://doi.org/10.1016/j.nmd.2013.11.006
doi: 10.1016/j.nmd.2013.11.006 pubmed: 24380807
Segers K, Kadhim H, Colson C, Duttmann R, Glibert G (2012) Adult polyglucosan body disease masquerading as ‘ALS with dementia of the Alzheimer type’: an exceptional phenotype in a rare pathology. Alzheimer Dis Assoc Disord. https://doi.org/10.1097/WAD.0b013e31821cc65d
doi: 10.1097/WAD.0b013e31821cc65d pubmed: 21572310
Caga J, Hsieh S, Lillo P, Dudley K, Mioshi E (2019) The impact of cognitive and behavioral symptoms on ALS patients and their caregivers. Front Neurol 10:192. https://doi.org/10.3389/fneur.2019.00192
doi: 10.3389/fneur.2019.00192 pubmed: 30915018 pmcid: 6421295
Figved N, Myhr K, Larsen J, Aarsland D (2007) Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. J Neurol Neurosurg Psychiatry 78(10):1097–1102. https://doi.org/10.1136/jnnp.2006.104216
doi: 10.1136/jnnp.2006.104216 pubmed: 17237144 pmcid: 2117557

Auteurs

Paul Theo Zebhauser (PT)

Department of Neurology, Technical University of Munich, School of Medicine, Munich, Germany. paul.zebhauser@tum.de.

Isabell Cordts (I)

Department of Neurology, Technical University of Munich, School of Medicine, Munich, Germany.

Holger Hengel (H)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

Bernhard Haslinger (B)

Department of Neurology, Technical University of Munich, School of Medicine, Munich, Germany.

Paul Lingor (P)

Department of Neurology, Technical University of Munich, School of Medicine, Munich, Germany.

Hasan Orhan Akman (HO)

Department of Neurology, Columbia University Medical Center, New York, NY, USA.

Tobias B Haack (TB)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Centre for Rare Diseases, University of Tuebingen, Tuebingen, Germany.

Marcus Deschauer (M)

Department of Neurology, Technical University of Munich, School of Medicine, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH